TOPK mediates immune evasion of renal cell carcinoma via upregulating the expression of PD-L1

Article Chemistry, Multidisciplinary

Identifying TOPK and Hypoxia Hallmarks in Esophageal Tumors for Photodynamic/ Chemo/Immunotherapy and Liver Metastasis Inhibition with Nanocarriers

Guidong Shi et al.

Summary: This study identified important therapeutic targets for esophageal squamous cell carcinoma (ESCC) and developed an effective nanocarrier-based approach for targeted therapy, aiming to improve treatment outcomes.

ACS NANO (2023)

添加到收藏夹

Article Chemistry, Multidisciplinary

Identifying TOPK and Hypoxia Hallmarks in Esophageal Tumors for Photodynamic/Chemo/Immunotherapy and Liver Metastasis Inhibition with Nanocarriers

Guidong Shi et al.

Summary: This study identified therapeutic targets for esophageal squamous cell carcinoma (ESCC) and developed a precise treatment method using nanoparticles, which can effectively kill cancer cells, diagnose tumors, and guide therapy.

ACS NANO (2023)

添加到收藏夹

Article Biochemistry & Molecular Biology

PBK/TOPK Is a Favorable Prognostic Biomarker Correlated with Antitumor Immunity in Colon Cancers

Dong-Hee Lee et al.

Summary: PBK/TOPK, a serine/threonine kinase, is associated with tumor immunity and prognosis in colon cancer. Elevated PBK/TOPK expression predicts a favorable outcome and is positively correlated with immune infiltration levels and T-cell cytotoxicity gene expression in colon cancer.

BIOMEDICINES (2022)

添加到收藏夹

Review Oncology

New first-line immunotherapy-based combinations for metastatic renal cell carcinoma: A systematic review and network meta-analysis

Pasquale Lombardi et al.

Summary: This study conducted a systematic review and network meta-analysis of first-line immune-checkpoints inhibitors (ICI) based combinations in metastatic renal cell carcinoma (mRCC). The results showed that lenvatinib plus pembrolizumab had the highest probability to be the best treatment in terms of overall survival (OS) and progression-free survival (PFS). In sarcomatoid patients, nivolumab plus cabozantinib ranked highest in survival outcomes.

CANCER TREATMENT REVIEWS (2022)

添加到收藏夹

Review Urology & Nephrology

European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update

Borje Ljungberg et al.

Summary: The European Association of Urology has prepared evidence-based guidelines for the management of RCC, which were updated in 2022 using a standardized methodology. The guidelines provide transparent and reliable evidence for the management of RCC, based on a thorough literature assessment and clinical practice recommendations.

EUROPEAN UROLOGY (2022)

添加到收藏夹

Article Cell Biology

TOPK/PBK is phosphorylated by ERK2 at serine 32, promotes tumorigenesis and is involved in sorafenib resistance in RCC

Huimin Sun et al.

Summary: TOPK is a highly expressed kinase in human tumors, and its activation is associated with poor prognosis in malignancies. The phosphorylation of TOPK at Thr9 and Ser32 is related to resistance to sorafenib.

CELL DEATH & DISEASE (2022)

添加到收藏夹

Review Biochemistry & Molecular Biology

Hallmarks of response, resistance, and toxicity to immune checkpoint blockade

Golnaz Morad et al.

Summary: This passage discusses the unprecedented advances in cancer treatment with immune checkpoint blockade (ICB), highlighting the critical need for insights into factors intrinsic and extrinsic to the host that impact ICB response and toxicity. There has been substantial progress in understanding the impact of host-intrinsic factors and the exposome on host physiology and response to treatment, representing the hallmarks of response, resistance, and toxicity to ICB in current day.

CELL (2021)

添加到收藏夹

Editorial Material Urology & Nephrology

The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care

Jens Bedke et al.

Summary: The recent trials have shown improved survival benefits with immune checkpoint inhibitor combinations in advanced kidney cancer, particularly with lenvatinib plus pembrolizumab, cabozantinib plus nivolumab, axitinib plus pembrolizumab, and ipilimumab plus nivolumab. These combination therapies are recommended as first-line treatments for advanced kidney cancer.

EUROPEAN UROLOGY (2021)

添加到收藏夹

Review Cell Biology

PBK/TOPK: A Therapeutic Target Worthy of Attention

Ziping Han et al.

Summary: Accumulating evidence suggests PBK/TOPK plays a role in mitosis and cell-cycle progression, with potential therapeutic implications in cancer. However, further research is needed to understand the applicability of PBK/TOPK inhibitors in clinical practice, given their overexpression in normal and pathological proliferative cells.

CELLS (2021)

添加到收藏夹

Article Cell Biology

USP19 exacerbates lipogenesis and colorectal carcinogenesis by stabilizing ME1

Yahui Zhu et al.

Summary: ERK2 phosphorylates ME1 at T103, inhibiting its degradation and promoting interaction with USP19. USP19 antagonizes RNF1-mediated ME1 degradation by deubiquitination, promoting lipid metabolism and NADPH production while suppressing ROS.

CELL REPORTS (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

PLK1/vimentin signaling facilitates immune escape by recruiting Smad2/3 to PD-L1 promoter in metastatic lung adenocarcinoma

Hay-Ran Jang et al.

Summary: The phosphorylation of vimentin by PLK1 activates TGF-beta signaling pathway in lung adenocarcinoma, leading to metastasis and immune escape through PD-L1 expression. Clinical relevance studies revealed an inverse correlation between the expressions of VIM, PLK1, and CD274 and the survival rates of patients with primary and metastatic lung adenocarcinoma.

CELL DEATH AND DIFFERENTIATION (2021)

添加到收藏夹

Review Oncology

PBK/TOPK: An Effective Drug Target with Diverse Therapeutic Potential

Hai Huang et al.

Summary: Cancer is a major global public health problem, and TOPK serves as a crucial factor in cell cycle regulation and mitotic progression. Abnormal overexpression or activation of TOPK in various cancers is associated with cancer development, dissemination, and poor prognosis. Targeting TOPK can be an important approach for cancer prevention and therapy.

CANCERS (2021)

添加到收藏夹

Review Oncology

Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma

Revati Sharma et al.

Summary: VEGF-TKIs have limited efficacy in treating RCC, as some patients develop drug resistance and others are innately resistant. Over the past decade, multiple molecular and genetic mechanisms of VEGF-TKI resistance have been reported. Recent studies have identified alternative mechanisms to the classical angiogenesis pathway in modulating resistance.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Targeting TOPK sensitises tumour cells to radiation-induced damage by enhancing replication stress

Katharine J. Herbert et al.

Summary: The study confirms the potential of TOPK as a target for treating solid tumors, shows that TOPK inhibitor in combination with radiation treatment can enhance efficacy, and reveals a previously unknown role of TOPK during S phase supporting cancer cell survival.

CELL DEATH AND DIFFERENTIATION (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology